NASDAQ
31.07.26 | 21:59
3,490 US-Dollar
-4,64 % -0,170
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | C4 Therapeutics presents cemsidomide data at EHA congress | 2 | Investing.com | ||
| 11.06. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory ... | 2 | GlobeNewswire (USA) | ||
| 11.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.05. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.05. | C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M | 1 | Seeking Alpha | ||
| 12.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 509 | GlobeNewswire (Europe) | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| 12.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Roche places a $1bn bet on C4T degrader-antibody conjugates | 9 | pharmaphorum | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 7 | Pharmaceutical Technology | ||
| 10.04. | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 29 | transkript.de | ||
| 09.04. | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 14 | Benzinga.com | ||
| 09.04. | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| 09.04. | C4 Therapeutics Enters Collaboration Agreement With Roche | 616 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 09.04. | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com | ||
| 09.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | 475 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 25.03. | Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock | 2 | Insider Monkey | ||
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,070 | -2,55 % | Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration | RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,595 | +4,12 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| CLINUVEL | 5,624 | -3,17 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,200 | -5,98 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,022 | -3,04 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 32,780 | -1,47 % | Celldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis | Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,630 | +3,95 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,746 | +0,61 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,395 | +1,59 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,960 | -5,45 % | Denali Therapeutics Inc.: Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 | ||
| CEL-SCI | 1,100 | +10,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| CYTOKINETICS | 67,30 | -3,53 % | Cytokinetics, Incorporated: Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales | Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,282 | +0,23 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,694 | -3,20 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,64 % bei einem Aktienkurs von 3,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.